{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"index.html","title":"Welcome to GrowthXInfinity","text":"<p>Deep, practical docs on portfolios, growth, and infinite learning for everyone.</p> <p></p> <ul> <li>Blogs</li> </ul>"},{"location":"blogs/index.html","title":"Blogs","text":"<p>Deep, practical docs on portfolios, growth, and infinite learning for everyone.</p> <p></p> <ul> <li>22-02-2026 Chandan Healthcare = Vaibhav Suryaavanshi of Indian Diagnostics? \ud83c\udfcf</li> <li>21-02-2026 Shaily Engineering Plastics = The Silent GLP-1 Proxy? \ud83d\udc89</li> <li>18-02-2026 Post Q3 FY26 Earnings Watchlist: Time to Recalibrate \ud83d\udcca</li> </ul>"},{"location":"blogs/18-02-2026-post-q3-fy26-earning-watchlist.html","title":"Post Q3 FY26 Earnings Watchlist: Time to Recalibrate \ud83d\udcca","text":"<p>Q3 FY26 earnings season is largely behind us.</p> <p>The next phase is not reaction \u2014 it is recalibration. Capital allocation now depends on execution, guidance, and balance sheet strength.</p> <p>Author: Priyanshu Jain, Date: 18-02-2026</p>"},{"location":"blogs/18-02-2026-post-q3-fy26-earning-watchlist.html#mainboard-companies-watchlist","title":"\ud83d\udcca Mainboard Companies Watchlist","text":"<p>Prices as of market close \u2014 18th February 2026.</p> Company Market Price (\u20b9) Jeena Sikho Life 717.70 V2 Retail 2,017.00 Manorama Industries 1,419.60 Vintage Coffee 145.05 Yatharth Hospital 693.35 Sky Gold &amp; Diamonds 378.40 BlackBuck 624.85 Frontier Springs 4,328.65 Arman Financial Services 1,703.00 Capri Global Capital 178.52 Kaynes Technology 4,057.50 Shaily 2,097.20 Neuland Laboratories 13,620.00 Coforge 1,372.80 Quality Power Electrical 879.35 Cupid 422.95 Senores Pharmaceuticals 822.10 Ceinsys Tech Price Pending Kernex Microsystem 1,137.60 India Grid Trust 164.32 <p>This basket spans: - Healthcare - Diagnostics - Specialty chemicals - Electronics manufacturing - NBFCs - Retail - Infra &amp; power - IT services</p> <p>Diversification remains thematic, not accidental.</p>"},{"location":"blogs/18-02-2026-post-q3-fy26-earning-watchlist.html#msme-space-watchlist","title":"\ud83c\udfed MSME Space Watchlist","text":"<p>Higher volatility. Higher execution dependency. Potentially higher operating leverage.</p> Company Market Price (\u20b9) Aimtron Electronics 848.00 Afcom Holdings 902.05 Chandan Healthcare 275.85 GSM Foils 207.90 Z-Tech (India) 540.25 OBSC Perfection 311.95 Krishna Defence 1,129.60 Shanti Gold International 217.58 V-Marc India 726.20 Grand Continent 123.00 Utssav CZ Gold Jewel 213.45 Bondada Engineering 341.30 Womancart 180.00 Sejal Glass 666.85 Kay Cee Energy &amp; Infra 133.15 Alpex Solar 811.95 <p>MSME names require: - Strong balance sheet monitoring - Working capital discipline - Order book visibility - Promoter credibility assessment</p> <p>Liquidity risk must be priced in.</p>"},{"location":"blogs/18-02-2026-post-q3-fy26-earning-watchlist.html#what-matters-post-earnings","title":"\ud83d\udcc8 What Matters Post Earnings","text":"<p>Post Q3, focus shifts to: - FY26 guidance vs delivery - Margin sustainability - Capex intensity vs cash flow - Debt trajectory - Order book execution - Working capital cycle</p> <p>Price alone does not determine opportunity. Earnings durability does.</p>"},{"location":"blogs/18-02-2026-post-q3-fy26-earning-watchlist.html#portfolio-allocation-framework","title":"\u2696\ufe0f Portfolio Allocation Framework","text":"<p>Structured monitoring approach: - Core compounders \u2192 Strong ROCE + steady earnings - Tactical growth \u2192 Expansion-led stories - High beta bets \u2192 MSME / early-stage operators - Yield stabilisers \u2192 InvITs / infra cash flow plays</p> <p>Rebalancing must be thesis-driven, not price-driven.</p>"},{"location":"blogs/18-02-2026-post-q3-fy26-earning-watchlist.html#final-take","title":"\ud83d\udd0d Final Take","text":"<p>Q3 FY26 provided clarity across sectors.</p> <p>The next 2\u20133 quarters will differentiate: - Narratives vs numbers - Guidance vs execution - Expansion vs returns</p> <p>A disciplined watchlist is not about tracking prices. It is about tracking business performance.</p> <pre><code>flowchart TD\n    A[Post Q3 Earnings Review]\n    A --&gt; B[Revenue &amp; Margin Trends]\n    B --&gt; C[Guidance &amp; Order Book]\n    C --&gt; D[Capex &amp; Debt Discipline]\n    D --&gt; E[Operating Leverage]\n    E --&gt; F[Cash Flow Visibility]\n    F --&gt; A</code></pre>"},{"location":"blogs/21-02-2026-shaily-engineering.html","title":"Shaily Engineering Plastics = The Silent GLP-1 Proxy? \ud83d\udc89","text":"<p>\u201cTum mote ho? Wazzan kam karna hai? Aajao\u2026 kara dunga.\u201d</p> <p>Light humour.</p> <p>But behind it lies a serious structural opportunity.</p> <p>As GLP-1 drugs fuel the global weight-loss and diabetes revolution, one Indian manufacturer is quietly building exposure to the delivery ecosystem \u2014 Shaily Engineering Plastics.</p> <p>Author: Priyanshu Jain, Date: 21-02-2026</p>"},{"location":"blogs/21-02-2026-shaily-engineering.html#the-glp-1-wave-is-structural","title":"\ud83c\udf0d The GLP-1 Wave Is Structural","text":"<p>GLP-1 drugs are witnessing exponential global demand driven by:</p> <ul> <li>Rising obesity levels  </li> <li>Increasing diabetes prevalence  </li> <li>Strong adoption across US &amp; Europe  </li> <li>Expanding physician acceptance  </li> </ul> <p>As drug volumes scale, demand does not stop at the molecule.</p> <p>It extends to:</p> <ul> <li>Precision injection pens  </li> <li>Drug delivery systems  </li> <li>High-spec medical-grade plastic components  </li> </ul> <p>And that\u2019s where the ecosystem players come in.</p>"},{"location":"blogs/21-02-2026-shaily-engineering.html#what-shaily-actually-does","title":"\ud83c\udfed What Shaily Actually Does","text":"<p>Shaily Engineering Plastics is a high-precision plastic components manufacturer serving regulated industries:</p> <ul> <li>Healthcare &amp; medical devices  </li> <li>Pharma delivery systems  </li> <li>Consumer &amp; industrial segments  </li> </ul> <p>In the GLP-1 segment, Shaily manufactures critical components used in injection pens \u2014 positioning itself as a supplier within a fast-growing therapeutic category.</p> <p>This is not a typical cyclical industrial story.</p> <p>It is a global healthcare trend-driven manufacturing opportunity.</p>"},{"location":"blogs/21-02-2026-shaily-engineering.html#why-device-suppliers-benefit","title":"\ud83d\udcb0 Why Device Suppliers Benefit","text":"<p>When GLP-1 drug volumes rise:</p> <ul> <li>More injection pens are required  </li> <li>Component suppliers scale production  </li> <li>Long-term supply contracts strengthen  </li> <li>High-precision manufacturers gain sticky business  </li> </ul> <p>Unlike drug developers, component suppliers face:</p> <ul> <li>Lower regulatory volatility  </li> <li>More predictable manufacturing scaling  </li> <li>Better operating leverage at high utilisation  </li> </ul> <p>The real leverage often sits behind the molecule.</p>"},{"location":"blogs/21-02-2026-shaily-engineering.html#expansion-strategic-shift","title":"\ud83d\ude80 Expansion &amp; Strategic Shift","text":"<p>Shaily has been actively:</p> <ul> <li>Expanding capacity to meet medical device demand  </li> <li>Investing in high-margin healthcare verticals  </li> <li>Deepening relationships with global pharma &amp; device companies  </li> <li>Increasing focus on regulated markets like US &amp; Europe  </li> </ul> <p>The company is gradually shifting revenue mix toward:</p> <ul> <li>Higher value-added precision healthcare products  </li> <li>Longer-term supply contracts  </li> <li>Better margin visibility  </li> </ul>"},{"location":"blogs/21-02-2026-shaily-engineering.html#the-patent-cliff-the-ecosystem-effect","title":"\ud83d\udd25 The Patent Cliff &amp; The Ecosystem Effect","text":"<p>As GLP-1 patents expire and generics enter:</p> <ul> <li>Drug prices fall  </li> <li>Volumes increase  </li> <li>Adoption widens globally  </li> </ul> <p>Generic manufacturers may create substitutes.</p> <p>But injection device ecosystems require:</p> <ul> <li>Precision  </li> <li>Reliability  </li> <li>Regulatory compliance  </li> <li>Established manufacturing partners  </li> </ul> <p>In the delivery system chain, scale and credibility matter.</p> <p>And ecosystem leaders tend to consolidate demand.</p>"},{"location":"blogs/21-02-2026-shaily-engineering.html#what-to-monitor","title":"\u26a0\ufe0f What To Monitor","text":"<ul> <li>Customer concentration risk  </li> <li>Capex execution efficiency  </li> <li>Dependency on specific GLP-1 programs  </li> <li>Regulatory changes in key export markets  </li> </ul> <p>Structural themes are powerful \u2014 but execution determines outcomes.</p>"},{"location":"blogs/21-02-2026-shaily-engineering.html#strategic-positioning","title":"\ud83c\udfaf Strategic Positioning","text":"<p>Shaily is not competing in the molecule race.</p> <p>It is participating in the infrastructure layer of a global healthcare trend.</p> <p>When a structural health shift meets niche manufacturing capability, long-term compounding potential emerges.</p> <p>Often, the real opportunity isn\u2019t the theme in headlines \u2014</p> <p>It\u2019s the proxy behind it.</p>"},{"location":"blogs/21-02-2026-shaily-engineering.html#final-take","title":"\ud83e\udde0 Final Take","text":"<p>The GLP-1 wave is real.</p> <p>Drug companies may dominate attention.</p> <p>But component suppliers embedded in the ecosystem may quietly benefit as volumes scale.</p> <p>Shaily represents a potential backend play on a front-end healthcare revolution.</p> <p>Execution, capacity utilisation, and customer stickiness will determine whether this remains thematic \u2014 or becomes structural compounding.</p> <pre><code>flowchart TD\n    A[Global GLP-1 Demand Surge]\n    A --&gt; B[Higher Drug Volumes]\n    B --&gt; C[More Injection Pens Required]\n    C --&gt; D[Precision Component Demand]\n    D --&gt; E[Shaily Manufacturing Scale]\n    E --&gt; F[Operating Leverage &amp; Margin Expansion]\n    F --&gt; G[Long-Term Compounding Potential]</code></pre>"},{"location":"blogs/22-02-2026-chandan-healthcare.html","title":"Chandan Healthcare = Vaibhav Suryaavanshi of Indian Diagnostics? \ud83c\udfcf","text":"<p>Some companies defend. Some attack.  </p> <p>Chandan Healthcare is clearly playing in the powerplay.</p> <p>Author: Priyanshu Jain, Date: 22-02-2026</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#q3-fy26-snapshot","title":"\ud83d\udcca Q3 FY26 Snapshot","text":"Metric Value Growth Revenue \u20b965.77 Cr +20% YoY EBITDA \u20b912.61 Cr +39% YoY EBITDA Margin 19.17% +263 bps PAT \u20b94.54 Cr \u2014 <p>Note: \u20b92.2 Cr one-time gratuity impact due to new labour code.</p> <p>Short-term provisioning aside, operating trajectory reflects improving leverage.</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#business-model-not-asset-light-infrastructure-led","title":"\ud83c\udfe5 Business Model: Not Asset-Light. Infrastructure-Led.","text":"<p>Unlike traditional franchise-heavy chains, Chandan builds 8,000\u20139,000 sq ft comprehensive centres offering:</p> <ul> <li>Pathology  </li> <li>Radiology (MRI, CT)  </li> <li>Corporate health check-ups  </li> <li>Government PPP projects  </li> <li>Direct B2C services  </li> <li>Franchise network  </li> </ul> <p>Integrated delivery enhances cross-selling, pricing control, and margin potential.</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#segment-ebitda-potential","title":"\ud83d\udcb0 Segment EBITDA Potential","text":"Segment EBITDA Potential B2C (Mature Centres) 40\u201345% B2G 30\u201340% B2B / Franchise ~35% <p>As centres mature:</p> <ul> <li>Fixed cost absorption improves  </li> <li>Radiology utilisation increases  </li> <li>Incremental revenue drops faster to EBITDA  </li> </ul> <p>This is operating leverage in action.</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#expansion-strategy-scale-with-intent","title":"\ud83d\ude80 Expansion Strategy: Scale With Intent","text":"<p>Recent additions:</p> <ul> <li>6 comprehensive centres  </li> <li>18 labs  </li> <li>Presence in 13 states  </li> </ul> <p>Pipeline:</p> <ul> <li>9 new labs  </li> <li>Genome Lab (Lucknow)  </li> <li>PET Scan facility (Gorakhpur)  </li> </ul>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#capex-plan","title":"Capex Plan","text":"<ul> <li>\u20b9100 Cr over 3 years  </li> <li>~\u20b91 Cr per lab  </li> </ul> <p>The model is capital-intensive but margin-accretive at maturity.</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#jeena-sikho-partnership-utilisation-upside","title":"\ud83e\udd1d Jeena Sikho Partnership: Utilisation Upside","text":"<ul> <li>\u20b92.5\u20133 lakh/day revenue currently  </li> <li>~30% coverage  </li> <li>Target: 100% coverage within 12 months  </li> </ul> <p>Same infrastructure. Higher throughput. Improving return ratios.</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#government-project-trigger-punjab-guwahati","title":"\ud83d\udd25 Government Project Trigger: Punjab + Guwahati","text":"<ul> <li>\u20b955 Cr annual visibility  </li> <li>10-year contract  </li> <li>Direct patient cash collection  </li> </ul> <p>No receivable drag.</p> <p>If executed efficiently, FY27 growth profile may materially shift upward.</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#strategic-positioning","title":"\ud83c\udfaf Strategic Positioning","text":"<p>Against large chains:</p> <ul> <li>Higher radiology penetration  </li> <li>Comprehensive centre format  </li> <li>Corporate affiliations  </li> </ul> <p>Against regional players:</p> <ul> <li>Brand scale  </li> <li>Wider test menu  </li> <li>Pricing efficiency  </li> </ul> <p>Positioned between premium nationals and fragmented locals.</p>"},{"location":"blogs/22-02-2026-chandan-healthcare.html#final-take","title":"\ud83e\udde0 Final Take","text":"<p>Chandan Healthcare is in expansion mode.</p> <p>The thesis depends on:</p> <ul> <li>Utilisation ramp-up  </li> <li>Capex discipline  </li> <li>Execution efficiency  </li> <li>Segment mix optimisation  </li> </ul> <p>If operating leverage materialises as projected, margin expansion could follow.</p> <p>Execution remains the decisive variable.</p> <pre><code>flowchart TD\n    A[Integrated Diagnostic Centres]\n    A --&gt; B[B2C + B2G + B2B Revenue Mix]\n    B --&gt; C[Higher Utilisation]\n    C --&gt; D[Operating Leverage]\n    D --&gt; E[Margin Expansion]\n    E --&gt; F[Stronger Cash Flow]\n    F --&gt; G[Reinvestment Into Expansion]\n    G --&gt; A</code></pre>"}]}